{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:19:51Z","timestamp":1787660391390,"version":"build-2736575974"},"reference-count":109,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"National Science Centre","doi-asserted-by":"publisher","award":["2019\/35\/O\/NZ2\/03761"],"award-info":[{"award-number":["2019\/35\/O\/NZ2\/03761"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"award":["2019\/35\/O\/NZ2\/03761"],"award-info":[{"award-number":["2019\/35\/O\/NZ2\/03761"]}],"id":[{"id":"https:\/\/ror.org\/03ha2q922","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>This review summarises current evidence on renal cell carcinoma (RCC) with sarcomatoid dedifferentiation (sRCC), with an emphasis on diagnosis, prognostic stratification, and treatment. Sarcomatoid dedifferentiation is characterised by high-grade spindle cell morphology, occurs in 2\u201326% of all RCC patients, predominantly in the clear cell subtype (~70%), and is WHO\/ISUP grade 4 regardless of extent of involvement. Thus, sRCC represents a pathological transformation rather than a distinct entity. Diagnosis requires biopsy or nephrectomy; immunohistochemical (IHC) retention of PAX8, cytokeratins, and vimentin alongside loss of subtype-specific markers distinguishes sRCC from primary renal sarcoma. On CT, sRCC typically presents as a large, heterogeneous mass with extensive necrosis; 18F-FDG PET\/CT carries independent prognostic value, though no feature is pathognomonic. Sarcomatoid features are approximately five times more prevalent in patients with metastatic vs. localised disease (~20 vs. ~4%), and their identification should prompt risk stratification. Median overall survival (OS) in metastatic sRCC is 5.9\u201313.3 months, though recent data suggest improvement with novel therapies. Sarcomatoid dedifferentiation is characterised by enrichment of alterations in TP53, BAP1, CDKN2A\/B, and NF2 on a background of founder RCC mutations, generating an immune-inflamed tumour microenvironment with elevated CD8+ T cell infiltration and PD-L1 expression that may underpin the heightened sensitivity of sRCC to immune checkpoint inhibitors (ICI). Surgery remains the cornerstone in localised disease, although recurrence rates approach 80% within two years. Adjuvant pembrolizumab significantly improved disease-free survival in high-risk localised RCC with sarcomatoid features (KEYNOTE-564; NCT03142334). In the metastatic setting, nivolumab plus ipilimumab and pembrolizumab plus axitinib are preferred first-line regimens.<\/jats:p>","DOI":"10.3390\/diagnostics16172711","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:27:19Z","timestamp":1787657239000},"page":"2711","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sarcomatoid Renal Cell Carcinoma: A Clinical Review"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5170-6348","authenticated-orcid":false,"given":"Piotr","family":"Remiszewski","sequence":"first","affiliation":[{"name":"Department of Soft Tissue\/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland"},{"name":"Medical Faculty, Medical University of Warsaw, 02-091 Warsaw, Poland"},{"name":"Outpatient Chemotherapy Department, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Szumera-Cie\u0107kiewicz","sequence":"additional","affiliation":[{"name":"Biobank, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2107-3810","authenticated-orcid":false,"given":"Anna M.","family":"Czarnecka","sequence":"additional","affiliation":[{"name":"Department of Soft Tissue\/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland"},{"name":"Outpatient Chemotherapy Department, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland"},{"name":"Department of Experimental Pharmacology, Mossakowski Medical Research Institute, Polish Academy of Sciences, 02-106 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Debien, V., Thouvenin, J., Lindner, V., Barth\u00e9l\u00e9my, P., Lang, H., Flippot, R., and Malouf, G.G. (2019). Sarcomatoid Dedifferentiation in Renal Cell Carcinoma: From Novel Molecular Insights to New Clinical Opportunities. Cancers, 12.","DOI":"10.3390\/cancers12010099"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.eururo.2014.05.027","article-title":"International Society of Urological Pathology Grading and Other Prognostic Factors for Renal Neoplasia","volume":"66","author":"Delahunt","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_3","first-page":"427.e17","article-title":"Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation","volume":"33","author":"Adibi","year":"2015","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.juro.2017.04.067","article-title":"Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras","volume":"198","author":"Keskin","year":"2017","journal-title":"J. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1200\/JCO.1999.17.2.523","article-title":"Sarcomatoid renal cell carcinoma: Biologic behavior, prognosis, and response to combined surgical resection and immunotherapy","volume":"17","author":"Cangiano","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_6","first-page":"100640","article-title":"The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma","volume":"33","author":"Hahn","year":"2022","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Pichler, R., Comp\u00e9rat, E., Klatte, T., Pichler, M., Loidl, W., Lusuardi, L., and Schmidinger, M. (2019). Renal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope?. Cancers, 11.","DOI":"10.3390\/cancers11030422"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/PAP.0000000000000018","article-title":"Epithelial-to-Mesenchymal Transition in Renal Neoplasms","volume":"21","author":"He","year":"2014","journal-title":"Adv. Anat. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41585-020-00382-9","article-title":"Sarcomatoid renal cell carcinoma: Biology, natural history and management","volume":"17","author":"Blum","year":"2020","journal-title":"Nat. Rev. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/00000478-200203000-00001","article-title":"Prognostic Impact of Histologic Subtyping of Adult Renal Epithelial Neoplasms","volume":"26","author":"Amin","year":"2002","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00000478-200103000-00001","article-title":"Sarcomatoid Differentiation in Renal Cell Carcinoma","volume":"25","author":"Moch","year":"2001","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/00000478-200404000-00002","article-title":"Sarcomatoid renal cell carcinoma: An examination of underlying histologic subtype and an analysis of associations with patient outcome","volume":"28","author":"Cheville","year":"2004","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00432-016-2304-3","article-title":"Presence of sarcomatoid differentiation as a prognostic indicator for survival in surgically treated metastatic renal cell carcinoma","volume":"143","author":"Gu","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/j.clgc.2019.01.005","article-title":"Sarcomatoid Renal Cell Carcinoma: Population-Based Study of 879 Patients","volume":"17","author":"Alevizakos","year":"2019","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/1097-0142(19870201)59:3<516::AID-CNCR2820590327>3.0.CO;2-W","article-title":"Sarcomatoid renal cell carcinoma: Clinicopathologic. A study of 42 cases","volume":"59","author":"Ro","year":"1987","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0022-5347(17)51388-9","article-title":"Sarcomatoid Renal Carcinoma","volume":"130","author":"Tomera","year":"1983","journal-title":"J. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0022-5347(17)43860-2","article-title":"Sarcomatoid Carcinoma of the Kidney","volume":"137","author":"Bertoni","year":"1987","journal-title":"J. Urol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1634\/theoncologist.2011-0227","article-title":"Sarcomatoid renal cell carcinoma: A comprehensive review of the biology and current treatment strategies","volume":"17","author":"Shuch","year":"2012","journal-title":"Oncologist"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jbo.2017.10.004","article-title":"Risk factors for bone metastasis from renal cell cancer","volume":"9","author":"Chen","year":"2017","journal-title":"J. Bone Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.clgc.2023.07.010","article-title":"Demographic Patterns and Clinicopathological Analysis of Sarcomatoid Renal Cell Carcinoma in US Population","volume":"22","author":"Ullah","year":"2023","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3233\/KCA-210126","article-title":"Sarcomatoid Renal Cell Carcinoma: The Present and Future of Treatment Paradigms","volume":"5","author":"Candelario","year":"2021","journal-title":"Kidney Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Park, H.K. (2023). The Metastasis Pattern of Renal Cell Carcinoma Is Influenced by Histologic Subtype, Grade, and Sarcomatoid Differentiation. Medicina, 59.","DOI":"10.3390\/medicina59101845"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40644-023-00535-0","article-title":"Sarcomatoid renal cell carcinoma: MRI features and their association with survival","volume":"23","author":"Cheng","year":"2023","journal-title":"Cancer Imaging"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s00261-014-0185-y","article-title":"MRI for differentiation of renal cell carcinoma with sarcomatoid component from other renal tumor types","volume":"40","author":"Takeuchi","year":"2015","journal-title":"Abdom. Imaging"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.juro.2010.06.105","article-title":"Percutaneous Biopsy of Primary Tumor in Metastatic Renal Cell Carcinoma to Predict High Risk Pathological Features: Comparison with Nephrectomy Assessment","volume":"184","author":"Abel","year":"2010","journal-title":"J. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.15586\/jkcvhl.2017.70","article-title":"The Pathology and Molecular Genetics of Sarcomatoid Renal Cell Carcinoma: A Mini-Review","volume":"4","author":"Wei","year":"2017","journal-title":"J. Kidney Cancer VHL"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6686","DOI":"10.1158\/1078-0432.CCR-17-1057","article-title":"Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape","volume":"23","author":"Wang","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.juro.2015.03.106","article-title":"Multi-Quadrant Biopsy Technique Improves Diagnostic Ability in Large Heterogeneous Renal Masses","volume":"194","author":"Abel","year":"2015","journal-title":"J. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Yu, W., Wang, Y., Jiang, Y., Zhang, W., and Li, Y. (2017). Distinct immunophenotypes and prognostic factors in renal cell carcinoma with sarcomatoid differentiation: A systematic study of 19 immunohistochemical markers in 42 cases. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3275-8"},{"key":"ref_30","unstructured":"Anderson, D.A., and Tretiakova, M. (2025, June 10). Sarcomatoid Renal Cell Carcinoma. Available online: https:\/\/www.pathologyoutlines.com\/topic\/kidneytumormalignantrccsarcoma.html."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.humpath.2007.02.002","article-title":"The evolution of collagen expression in sarcomatoid renal cell carcinoma","volume":"38","author":"Delahunt","year":"2007","journal-title":"Hum. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1097\/PAS.0b013e3181dc5e8a","article-title":"PAX8 (+)\/p63 (-) immunostaining pattern in renal collecting duct carcinoma (CDC): A useful immunoprofile in the differential diagnosis of CDC versus urothelial carcinoma of upper urinary tract","volume":"34","author":"Albadine","year":"2010","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1016\/j.humpath.2013.07.006","article-title":"The role of GATA binding protein 3 in the differential diagnosis of collecting duct and upper tract urothelial carcinomas","volume":"44","author":"Albadine","year":"2013","journal-title":"Hum. Pathol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.4103\/jcrt.JCRT_107_19","article-title":"Primary leiomyosarcoma kidney\u2014A rare entity with a diagnostic challenge","volume":"18","author":"Chaudhary","year":"2022","journal-title":"J. Cancer Res. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Choi, J.H., and Ro, J.Y. (2020). Retroperitoneal Sarcomas: An Update on the Diagnostic Pathology Approach. Diagnostics, 10.","DOI":"10.3390\/diagnostics10090642"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.clgc.2014.12.001","article-title":"Using percentage of sarcomatoid differentiation as a prognostic factor in renal cell carcinoma","volume":"13","author":"Kim","year":"2014","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0022-5347(05)65384-0","article-title":"Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma","volume":"167","author":"Mian","year":"2002","journal-title":"J. Urol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","article-title":"The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours","volume":"82","author":"Moch","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1097\/PAS.0b013e318299f0fb","article-title":"The International Society of Urological Pathology grading system for renal cell carcinoma and other prognostic parameters","volume":"37","author":"Delahunt","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_40","unstructured":"International Collaboration on Cancer Reporting (2026, February 01). Datasets for Reporting Renal Epithelial Neoplasms\/Carcinoma of Renal Tubular Origin. ICCR Structured Pathology Reporting Resources. Available online: https:\/\/www.iccr-cancer.org."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1007\/s00345-018-2447-8","article-title":"WHO\/ISUP classification, grading and pathological staging of renal cell carcinoma: Standards and controversies","volume":"36","author":"Warren","year":"2018","journal-title":"World J. Urol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"26","DOI":"10.15586\/jkcvhl.2014.11","article-title":"The ISUP system of staging, grading and classification of renal cell neoplasia","volume":"1","author":"Samaratunga","year":"2014","journal-title":"J. Kidney Cancer VHL"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.humpath.2012.12.012","article-title":"Use of PAX8 and GATA3 in diagnosing sarcomatoid renal cell carcinoma and sarcomatoid urothelial carcinoma","volume":"44","author":"Chang","year":"2013","journal-title":"Hum. Pathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4149\/neo_2022_221004N984","article-title":"Real-life experience of patients with sarcomatoid renal cell carcinoma: A multicenter retrospective study","volume":"70","author":"Almuradova","year":"2023","journal-title":"Neoplasma"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2214\/AJR.14.13279","article-title":"Diagnosis of Sarcomatoid Renal Cell Carcinoma with CT: Evaluation by Qualitative Imaging Features and Texture Analysis","volume":"204","author":"Schieda","year":"2015","journal-title":"Am. J. Roentgenol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2214\/AJR.19.22467","article-title":"FDG PET\/CT and CT Findings of Renal Cell Carcinoma with Sarcomatoid Differentiation","volume":"215","author":"Zhu","year":"2020","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00345-016-1780-z","article-title":"Comparison of oncologic outcomes between sarcomatoid and clear cell renal cell carcinoma","volume":"34","author":"Trudeau","year":"2016","journal-title":"World J. Urol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/cncr.24768","article-title":"Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy","volume":"116","author":"Shuch","year":"2010","journal-title":"Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00345-015-1644-y","article-title":"Histologic subtype impacts cancer-specific survival in patients with sarcomatoid-variant renal cell carcinoma treated surgically","volume":"34","author":"Nguyen","year":"2015","journal-title":"World J. Urol."},{"key":"ref_50","first-page":"166.e21","article-title":"Clinically non-metastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent","volume":"33","author":"Merrill","year":"2015","journal-title":"Urol. Oncol.-Semin. Orig. Investig."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/bju.12781","article-title":"A novel prognostic model for patients with sarcomatoid renal cell carcinoma","volume":"115","author":"Zhang","year":"2014","journal-title":"BJU Int."},{"key":"ref_52","first-page":"265","article-title":"Sarcomatoid renal cell carcinoma: Biology and treatment advances","volume":"36","author":"Mouallem","year":"2018","journal-title":"Urol. Oncol.\u2014Semin. Orig. Investig."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41598-020-57534-5","article-title":"Molecular scharacterisation of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers","volume":"10","author":"Malouf","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41467-021-21068-9","article-title":"Integrative molecular scharacterisation of sarcomatoid and rhabdoid renal cell carcinoma","volume":"12","author":"Bakouny","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1073\/pnas.1525735113","article-title":"Genomic scharacterisation of sarcomatoid transformation in clear cell renal cell carcinoma","volume":"113","author":"Bi","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ccell.2020.10.011","article-title":"Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade","volume":"38","author":"Motzer","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3349\/ymj.2023.0587","article-title":"Incidence and Pattern of Recurrence after Surgical Resection in Organ-Confined Renal Cell Carcinoma","volume":"65","author":"Kim","year":"2024","journal-title":"Yonsei Med. J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.euros.2024.10.002","article-title":"Trends and Outcomes in Sarcomatoid Renal Cell Carcinoma: Analysis of the National Cancer Data Base","volume":"71","author":"Wang","year":"2025","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"w30175","DOI":"10.4414\/SMW.2022.w30175","article-title":"Incidence and outcome of patients with renal cell carcinoma treated with partial or radical nephrectomy in the Cantons St Gallen and Appenzell 2009\u20132018","volume":"152","author":"Aeppli","year":"2022","journal-title":"Swiss Med. Wkly."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"250","DOI":"10.21037\/tau.2020.02.19","article-title":"Propensity-score matched comparison of partial versus radical nephrectomy for T1N0M0 sarcomatoid renal cell carcinoma","volume":"9","author":"Ji","year":"2020","journal-title":"Transl. Androl. Urol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.urology.2019.09.044","article-title":"UK Multicenter Prospective Evaluation of the Leibovich Score in Localized Renal Cell Carcinoma: Performance has Altered Over Time","volume":"136","author":"Vasudev","year":"2020","journal-title":"Urology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/ajcp\/aqw059","article-title":"Radical Nephrectomy for Renal Cell Carcinoma: Its Contemporary Role Related to Histologic Type, Tumor Size, and Nodal Status: A Retrospective Study","volume":"145","author":"Mirza","year":"2016","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.urology.2019.08.058","article-title":"The Role of Cytoreductive Nephrectomy for Sarcomatoid Renal Cell Carcinoma: A 29-Year Institutional Experience","volume":"136","author":"Silagy","year":"2020","journal-title":"Urology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/iju.12457","article-title":"Lymph node dissection during cytoreductive nephrectomy: A retrospective analysis","volume":"21","author":"Feuerstein","year":"2014","journal-title":"Int. J. Urol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1200\/JCO.2018.79.0246","article-title":"Surgical Management of Advanced Kidney Cancer: The Role of Cytoreductive Nephrectomy and Lymphadenectomy","volume":"36","author":"Patel","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s12032-011-9829-8","article-title":"A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802","volume":"29","author":"Haas","year":"2011","journal-title":"Med. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1002\/cncr.29503","article-title":"Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and\/or poor-risk metastatic renal cell carcinoma","volume":"121","author":"Michaelson","year":"2015","journal-title":"Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1007\/s12032-010-9649-2","article-title":"Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy","volume":"28","author":"Dutcher","year":"2011","journal-title":"Med. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0022-5347(05)64551-X","article-title":"Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: A phase II study of the Genitourinary Group of the French Federation of Cancer Centers","volume":"168","author":"Escudier","year":"2002","journal-title":"J. Urol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2178217","DOI":"10.1080\/21645515.2023.2178217","article-title":"The emerging landscape of neo\/adjuvant immunotherapy in renal cell carcinoma","volume":"19","author":"Dibajnia","year":"2023","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(22)01658-0","article-title":"Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): A multicentre, randomised, double-blind, phase 3 trial","volume":"400","author":"Pal","year":"2022","journal-title":"Lancet"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/bju.15981","article-title":"Adjuvant immunotherapy in renal cell carcinoma: A systematic review and meta-analysis","volume":"131","author":"Riveros","year":"2023","journal-title":"BJU Int."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s11255-015-1093-y","article-title":"Does postoperative radiation therapy impact survival in non-metastatic sarcomatoid renal cell carcinoma? A SEER-based study","volume":"47","author":"Eminaga","year":"2015","journal-title":"Int. Urol. Nephrol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.critrevonc.2018.08.010","article-title":"Stereotactic body radiation therapy (SBRT) on renal cell carcinoma, an overview of technical aspects, biological rationale and current literature","volume":"131","author":"Francolini","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1748-717X-6-34","article-title":"Stereotactic body radiation therapy for melanoma and renal cell carcinoma: Impact of single fraction equivalent dose on local control","volume":"6","author":"Kavanagh","year":"2011","journal-title":"Radiat. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1016\/j.juro.2009.07.049","article-title":"Cytoreductive Nephrectomy for Kidney Cancer with Sarcomatoid Histology\u2014Is Up-Front Resection Indicated and, if Not, is it Avoidable? J","volume":"182","author":"Shuch","year":"2009","journal-title":"Urol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.juro.2016.03.144","article-title":"The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis","volume":"196","author":"Thomas","year":"2016","journal-title":"J. Urol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.euo.2018.08.028","article-title":"Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review","volume":"2","author":"Ouzaid","year":"2019","journal-title":"Eur. Urol. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e502","DOI":"10.1016\/j.wneu.2017.10.011","article-title":"Radiosurgery for Treatment of Renal Cell Metastases to Spine: A Systematic Review of the Literature","volume":"109","author":"Smith","year":"2018","journal-title":"World Neurosurg."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/iju.12502","article-title":"Current management and future perspectives of metastatic renal cell carcinoma","volume":"21","author":"Lester","year":"2014","journal-title":"Int. J. Urol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11748-016-0623-6","article-title":"Pulmonary metastasectomy from renal cell carcinoma including 3 cases with sarcomatoid component","volume":"64","author":"Ueno","year":"2016","journal-title":"Gen. Thorac. Cardiovasc. Surg."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1002\/ijc.35141","article-title":"Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid dedifferentiation (ARON-1 study)","volume":"155","author":"Ciccarese","year":"2024","journal-title":"Int. J. Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Zhi, H., Feng, M., Liu, S., Na, T., Zhang, N., and BiLiGe, W. (2020). Prognostic Significance of Sarcomatoid Differentiation in Patients with Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.591001"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejca.2020.06.008","article-title":"Patients with sarcomatoid renal cell carcinoma\u2014Re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors","volume":"136","author":"Iacovelli","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"27","DOI":"10.15586\/jkcvhl.v11i2.309","article-title":"Active Surveillance in Metastatic Renal Cell Carcinoma","volume":"11","author":"Beecroft","year":"2024","journal-title":"J. Kidney Cancer VHL"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1200\/JCO.2023.41.6_suppl.687","article-title":"Impact of sarcomatoid features on treatment outcomes in metastatic clear cell renal cell carcinoma treated with first-line immunotherapy combinations","volume":"41","author":"Fitzgerald","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1016\/j.clgc.2014.08.011","article-title":"Outcome of patients with metastatic sarcomatoid renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium","volume":"13","author":"Kyriakopoulos","year":"2014","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e005445","DOI":"10.1136\/jitc-2022-005445","article-title":"Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma","volume":"10","author":"Rini","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1200\/JCO.20.02365","article-title":"Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma","volume":"39","author":"McDermott","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): Extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.20.02363","article-title":"Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients with Advanced Clear Cell Renal Cell Carcinoma","volume":"39","author":"McDermott","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"100101","DOI":"10.1016\/j.esmoop.2021.100101","article-title":"Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: Post hoc analysis of a randomised clinical trial","volume":"6","author":"Choueiri","year":"2021","journal-title":"ESMO Open"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Gr\u00fcnwald, V., Powles, T., Eto, M., Kopyltsov, E., Rha, S.Y., Porta, C., Motzer, R., Hutson, T.E., M\u00e9ndez-Vidal, M.J., and Hong, S.H. (2023). Phase 3 CLEAR study in patients with advanced renal cell carcinoma: Outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. Front. Oncol., 13, Erratum in Front. Oncol. 2024, 13, 1343027. https:\/\/doi.org\/10.3389\/fonc.2023.1343027.","DOI":"10.3389\/fonc.2023.1223282"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.eururo.2020.06.021","article-title":"Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: Prespecified Subgroup Analysis of IMmotion151","volume":"79","author":"Rini","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamaoncol.2021.5981","article-title":"Final Overall Survival and Molecular Analysis in Metastatic RCC: IMmotion151","volume":"8","author":"Motzer","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.annonc.2025.03.016","article-title":"Prospective randomized phase-II trial of ipilimumab\/nivolumab versus standard of care in non-clear cell renal cell cancer\u2014Results of the SUNNIFORECAST trial","volume":"36","author":"Bergmann","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Electronic address: Clinicalguidelines@esmo.org. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Powles","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.eururo.2025.02.020","article-title":"European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update","volume":"87","author":"Bex","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.annonc.2026.02.017","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Final analysis of efficacy and safety from the phase III CheckMate 214 trial","volume":"37","author":"Choueiri","year":"2026","journal-title":"Ann. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1158\/1078-0432.CCR-20-2063","article-title":"Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid RCC","volume":"27","author":"Tannir","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1200\/JCO.2025.43.5_suppl.439","article-title":"Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial","volume":"43","author":"Motzer","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.annonc.2020.04.010","article-title":"Updated efficacy results from the JAVELIN Renal 101 trial: First-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma","volume":"31","author":"Choueiri","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/oncolo\/oyad302","article-title":"Treatment Outcomes in Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid and\/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy","volume":"29","author":"Hahn","year":"2024","journal-title":"Oncologist"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/17\/2711\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:31:56Z","timestamp":1787657516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/17\/2711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":109,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["diagnostics16172711"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16172711","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]}}}